Home › NCT04938765

Effect of Magnesium Sulfate Bolus on Intraoperative Neuromonitoring

Randomized and Placebo Controlled Study to Evaluate the Effect of Magnesium Sulfate on Intraoperative Neuromonitoring.

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria.

* Patients aged 18 to 80 years
* Belonging to American Society of Anesthesiologists physical status (ASA) I, II
* Undergoing elective spine or cranial surgery where intraoperative neuromonitoring including short latency somatosensory evoked potentials (SSEP or SEP) and transcranial electrical muscle motor evoked potentials recording from muscles (TceMEP or TcMEP or mMEP or MEP) is planned.

Exclusion Criteria:

* Magnesium use within the last 2 days, either intravenous or oral supplements.
* Patients with known electrolyte imbalances (Sodium \<135 or \>145 mmol/L OR Potassium \< 3.5 or \> 5.0 mmol/L, Magnesium \>1.2 mmol/L.
* Severe cardiac or cardiac conduction disorders.
* Severe pulmonary disease.
* Patients with significant neuromuscular disorders or preexisting motor or sensory deficits other than focal upper limb neuropathy or focal cervical radiculopathy or mild cervical myelopathy.
* Severe Renal disease - serum creatinine of \> 2 mg/dl.
* Pregnant or breastfeeding patients.
* Unable to obtain adequate baseline SSEPs and MEPs.

About the study

Magnesium Sulfate(MgSo4) is increasingly being used as part of the multimodal pain regimen in the perioperative period. The intraoperative neurophysiological monitoring (IONM) is utilized in complex spine and cranial surgeries to assess the functional integrity of the neural pathways. The effect of Magnesium sulfate on IONM has not been studied.

This is a prospective, double blind, randomized placebo controlled trial to study the effect of Magnesium sulfate bolus on the amplitude and latency of somatosensory(SSEPs) and motor evoked potentials(MEPs) in patients undergoing surgery requiring IONM.

What is being tested

• Magnesium sulfate (drug)
• Normal Saline (drug)

Sponsor: Loma Linda University · Participants: 50 · Started: Mar 18, 2022

Contact the study team

• Rashmi Vandse, MD · Phone: 9095584000

Official record on ClinicalTrials.gov — NCT04938765

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.